Literature DB >> 33184179

Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.

Chengliang Yang1, Elizabeth Liu1, Mingyao Liu2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33184179      PMCID： PMC7720215          DOI： 10.1073/pnas.2009253117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  7 in total

1.  Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.

Authors:  Savino Sciascia; Franco Aprà; Alessandra Baffa; Simone Baldovino; Daniela Boaro; Roberto Boero; Stefano Bonora; Andrea Calcagno; Irene Cecchi; Giacoma Cinnirella; Marcella Converso; Martina Cozzi; Paola Crosasso; Fabio De Iaco; Giovanni Di Perri; Mario Eandi; Roberta Fenoglio; Massimo Giusti; Daniele Imperiale; Gianlorenzo Imperiale; Sergio Livigni; Emilpaolo Manno; Carlo Massara; Valeria Milone; Giuseppe Natale; Mauro Navarra; Valentina Oddone; Sara Osella; Pavilio Piccioni; Massimo Radin; Dario Roccatello; Daniela Rossi
Journal:  Clin Exp Rheumatol       Date:  2020-05-01       Impact factor: 4.473

2.  Tocilizumab treatment in COVID-19: A single center experience.

Authors:  Pan Luo; Yi Liu; Lin Qiu; Xiulan Liu; Dong Liu; Juan Li
Journal:  J Med Virol       Date:  2020-04-15       Impact factor: 2.327

3.  Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.

Authors:  Jared Radbel; Navaneeth Narayanan; Pinki J Bhatt
Journal:  Chest       Date:  2020-04-25       Impact factor: 9.410

4.  Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.

Authors:  Saeed K Alzghari; Valerie S Acuña
Journal:  J Clin Virol       Date:  2020-04-21       Impact factor: 3.168

5.  Effective treatment of severe COVID-19 patients with tocilizumab.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-29       Impact factor: 11.205

Review 6.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  James M Sanders; Marguerite L Monogue; Tomasz Z Jodlowski; James B Cutrell
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

7.  The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.

Authors:  Zhenwei Yang; Jialong Liu; Yunjiao Zhou; Xixian Zhao; Qiu Zhao; Jing Liu
Journal:  J Infect       Date:  2020-04-10       Impact factor: 6.072
  7 in total
  4 in total

1.  Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention.

Authors:  Xiaoling Xu; Mingfeng Han; Tiantian Li; Wei Sun; Dongsheng Wang; Binqing Fu; Yonggang Zhou; Xiaohu Zheng; Yun Yang; Xiuyong Li; Xiaohua Zhang; Aijun Pan; Haiming Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-12       Impact factor: 11.205

Review 2.  Safety profile of COVID-19 drugs in a real clinical setting.

Authors:  Mei Nee Chiu; Maitry Bhardwaj; Sangeeta Pilkhwal Sah
Journal:  Eur J Clin Pharmacol       Date:  2022-01-28       Impact factor: 3.064

3.  Real-world evidence of the use of glucocorticoids for severe COVID-19.

Authors:  Alejandra Albarrán-Sánchez; Claudia Ramírez-Rentería; Moisés Mercado; Miriam Sánchez-García; Corazón de Jesús Barrientos-Flores; Aldo Ferreira-Hermosillo
Journal:  Ther Adv Endocrinol Metab       Date:  2022-01-19       Impact factor: 3.565

Review 4.  Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.

Authors:  Mohammad Mahdi Rezaei Tolzali; Maryam Noori; Pourya Shokri; Shayan Rahmani; Shokoufeh Khanzadeh; Seyed Aria Nejadghaderi; Asra Fazlollahi; Mark J M Sullman; Kuljit Singh; Ali-Asghar Kolahi; Shahnam Arshi; Saeid Safiri
Journal:  Rev Med Virol       Date:  2022-08-27       Impact factor: 11.043
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.